Prestige Hospitality

Prestige BioPharma is a Singapore-based biopharmaceutical company specializing in the development of biosimilars and innovative antibody therapeutics. The company's lead biosimilar candidate, Tuznue (HD201), targets HER2-positive breast and gastric cancers and has undergone regulatory review in multiple jurisdictions. Its innovative pipeline is headlined by PBP1510 (ulenistamab), a first-in-class monoclonal antibody targeting PAUF for the treatment of pancreatic cancer, which has received Orphan Drug Designation from the FDA and EMA. Prestige BioPharma operates a vertically integrated model with its affiliate, Prestige BioLogics, providing dedicated CDMO services. The company is publicly traded on the Korea Exchange (KOSPI).